Excessive
weight gain in a subset of intensively treated Diabetes Control and Complications Trial (DCCT) subjects was associated with higher waist to hip ratio; higher
triglyceride (TG),
low-density lipoprotein (
LDL) cholesterol, and
apolipoprotein B (
ApoB) in the presence of small-dense
LDL; and decreased
high-density lipoprotein 2 cholesterol (HDL2-C), suggesting that
weight gain in these subjects resulted in higher intraabdominal fat (IAF), and an atherosclerotic
dyslipidemia mediated through hepatic
lipase activity (HL). Objectives were to investigate relationships between IAF, HL, and
dyslipidemia and to relate IAF to previous body mass index change during the DCCT. Sixty-one subjects were studied approximately 4 yr after DCCT closeout. IAF was positively related to HL (P < 0.001). IAF positively correlated with logTG (P < 0.001) and
ApoB (P < 0.001), and negatively with
LDL relative flotation rate (P < 0.001) and logHDL2-C (P = 0.001). HL accounted for most of the relationship between IAF with logHDL2-C and
LDL relative flotation rate, and none of the relationship between IAF and logTG or
ApoB. DCCT-related body mass index change accounted for a significant portion of logIAF variance measured 4 yr later (P < 0.001). Elevated IAF in subjects with
type 1 diabetes was related to an atherosclerotic
dyslipidemia similar to that seen in individuals without diabetes who have
metabolic syndrome. DCCT-related
weight gain positively correlated with subsequent IAF.